title: [Laryngeal cancer treatment outcomes in our department].
abstract: Laryngeal cancer is one of the most common types of head and neck cancer. Numerous studies have reported treatment outcomes, and therapeutic approaches and results are generally well established. However, the widespread use of concurrent chemoradiation therapy(CCRT)has led to differences among hospitals in laryngeal preservation rates in patients with T2 and T3 tumors. CCRT is the mainstay of treatment for laryngeal cancer in our department, given our goals of achieving organ and functional preservation, as well as radical cure. Our regimen for CCRT is comprised of chemotherapy with S-1 plus nedaplatin, concurrently with radiation therapy(SN therapy). We report outcomes obtained from 60 patients with laryngeal cancer who received first-line treatment in our department from April 2005 through March 2010. Cumulative survival rates according to disease stage were as follows: Stage I, 100%; Stage II, 96. 2%; Stage III, 83. 3%; and Stage IV, 48. 8%. The complete response rate after SN therapy was 84. 3%. After excluding patients with T4 tumors, the laryngeal preservation rate was 85. 7%.
authors.affiliation: Dept. of Otorhinolaryngology, Showa University Fujigaoka Hospital.
authors.forename: Shunya
authors.initials: S
authors.lastname: Egawa
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Shimane
authors.forename: Rio
authors.initials: R
authors.lastname: Akiyama
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Ikenoya
authors.forename: Aya
authors.initials: A
authors.lastname: Uzuki
authors.forename: Akane
authors.initials: A
authors.lastname: Sugimoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Kenichirou
authors.initials: K
authors.lastname: Ikeda
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Sanbe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; C053989:nedaplatin